SITC Cancer Immunotherapy CONNECT

Stay Current with FDA-Approved Immunotherapy Treatments
Attend an upcoming SITC Advances in Cancer Immunotherapy™ Program

Louisville, Ky. | Pittsburgh


4 Cancer Moonshot ProgramSM Funding Opportunity Announcements
View the recently published funding opportunities announcements by the National Institutes of Health.

Click Here


SITC Congratulates 2018 Nobel Laureates James P. Allison, PhD, and Tasuku Honjo, MD, PhD



Join a SITC Professional Interest Community

Create new collaborations, build your professional network and discuss the latest research trends in SITC Professional Interest Communities.

Learn More and Join Today


JITC Earns Impact Factor of 8.374


 The Journal for ImmunoTherapy of Cancer (JITC) received its first impact factor of 8.374! JITC’s impact factor ranks in the top 8 percent of all journals published in the categories of oncology and immunology.




Learn the Value of 

member-ribbon-v4.pngSee members discuss the benefits of a SITC membership in this new video.

Watch The Video


Explore resources and educational opportunities for cancer patients and those who advocate for them.







Track the latest advancements and educational opportunities in cancer immunotherapy and immunology.







Advance science, submit your manuscript and monitor the global progress of cancer immunotherapy research.






Latest Discussions

  • Posted in: Women in SITC

    Brenda Ernest and Mirdula George I already e-know you from our other group, glad to see you here. Feel free to introduce yourself! Priscila ------------------------------ Priscila Goncalves Associate Director Center for Novel Cancer Therapies Northwell ...

  • Posted in: Women in SITC

    Hi ladies Now that we enjoyed the SITC 2018 meeting in DC. Who is planning on going to the ASCO-SITC Meeting in Feb 2019 in San Fran.  I would love to meet some of you in person and hear some of your ideas on how SITC can help our careers. Priscila ------------------------------ ...

  • The cited editorial states that even with modest survival benefits, tripling of PFS as related to the PACIFIC trial of use of durvalumab immediately after chemoradiotherapy is commendable. Given minimal side effects, its addition should be considered ...

Follow the SITC Twitter Feed.


Connect with colleagues at these Upcoming Events.


Ignite the SITC Sparkathon

Donate today to support early career scientists who are emerging leaders seeking to advance research in the cancer immunotherapy field.


Learn More


The Journal & The Blog

Journal for ImmunoTherapy of Cancer

An open access, peer-reviewed journal, the Journal for ImmunoTherapy of Cancer (JITC) is the global voice of the society, producing original research articles, literature reviews and more on tumor immunology and cancer immunotherapy.

Learn More


Making Cure a Reality

It is the mission of the Society for Immunotherapy of Cancer (SITC) to improve cancer patient outcomes by advancing the science, development and application of cancer immunology and immunotherapy through our core values of interaction/integration, innovation, translation and leadership in the field. SITC aims to make cancer immunotherapy a standard of care and the word “cure” a reality for cancer patients everywhere.


Learn More